Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Chronic Lymphocytic Leukemia Therapeutics Market (2015-2023) – Grow Pricing, Features, Reviews & Comparison of Alternatives.

Tuesday, March 7, 2017 4:49
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Latest industry research report on Chronic Lymphocytic Leukemia Therapeutic Market. Chronic Lymphocytic Leukemia (CLL) is a type of hematological malignancy marked by excessive proliferation of abnormal white blood cells.

 CLL predominantly affects the B-cell lymphocytes which are involved in the production of antibodies to fight against infections and foreign antigens. Rising incidence of CLL coupled with a high rate of mortality, demonstrates the unmet market need for better therapeutics.

According to the American Cancer Society (ACS) estimate, more than 14000 new cases and more than 4,500 deaths are expected in the year 2015. CLL is more common among the aging population, with a higher frequency in the people aged 70 or above.Family history of blood disorders and excessive exposure to harmful chemicals are the two important drivers for CLL treatment market.

Get Free Sample Report Of Chronic Lymphocytic Leukemia Therapeutic Market @ http://www.marketresearchstore.com/report/world-chronic-lymphocytic-leukemia-therapeutics-market-opportunities-71711#RequestSample

Higher incidences of leukemia coupled with improved diagnosis for CLL, growing disease awareness and rising incidences of comorbidities, especially among elders are other factors significant in determining the market growth. Furthermore, breakthrough therapy designation by FDA and discovery of some pipeline drugs would further accelerate the market growth. However, high cost of treatment, is likely to curtail the market growth.

For instance, GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of relapsed CLL. Arzerra is a monoclonal antibody which targets CD20 molecule on the surface of CLL cells. Recently, Venetoclax, an investigational drug for the treatment of relapse or refractory CLL, has been granted Breakthrough Therapy Designation by US FDA. The drug is being developed by AbbVie in collaboration with Genentech and Roche.

Do Inquiry To Buy Report Of Chronic Lymphocytic Leukemia Therapeutic Market @ http://www.marketresearchstore.com/report/world-chronic-lymphocytic-leukemia-therapeutics-market-opportunities-71711#InquiryForBuying

The global Chronic Lymphocytic Leukemia Therapeutics market is segmented below:

Chronic Lymphocytic Leukemia Therapeutics Market By Drug Type

  • Chemotherapy Drugs
  • Targeted Therapy
  • Approved Drugs
  • Pipeline Drugs
  • Others

Chronic Lymphocytic Leukemia Therapeutics Market By Route of Administration

  • Oral Drugs
  • Intravenous Drugs
  • Others

Chronic Lymphocytic Leukemia Therapeutics Market By Geography

  • North America
  • Europe
  • AsiaPacific
  • LAMEA

About Market research Store

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

Contact Us:

Joel John
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442, USA
USA Tel: +1-386-310-3803
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: sales@marketresearchstore.com
Web: http://www.marketresearchstore.com/

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.